Contineum Therapeutics CEO Carmine Stengone disposes of shares worth $40,029

Reuters2026/08/03 22:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Contineum Therapeutics CEO and President Carmine N. Stengone sold 2,500 Class A common shares at USD 16.01 on Aug. 3, 2026.
He acquired 2,500 Class A common shares at USD 1.01 via option exercise the same day.
Directly held Class A common shares fell to 17,217 from 19,717.
Stock options beneficially owned declined to 276,930 from 279,430.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-052031), on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Contineum Therapeutics CEO Carmine Stengone disposes of shares worth $40,029

You may also like

Crypto prices

Contineum Therapeutics CEO Carmine Stengone disposes of shares worth $40,029﻿

You may also like

Crypto prices

Contineum Therapeutics CEO Carmine Stengone disposes of shares worth $40,029